Covalon Technologies Ltd. reports company developments across advanced medical technologies for vascular access, infection prevention, wound care, and surgical consumables. Recurring updates describe clinical education, healthcare-conference activity, and product use around contamination of intravenous connections, healthcare-associated infection risk, skin integrity, and patient-care workflows.
Covalon news also includes fiscal results, management discussion and analysis availability, shareholder meeting matters, director compensation through deferred share units, and amendments to governance documents and incentive plans. Product-specific coverage includes solutions such as CovaClear IV Cover dressings and VALGuard Vascular Access Line Guard.
Covalon (OTCQX: CVALF, TSXV: COV) declared its first-ever special cash dividend totaling CAD 4,112,711.55 (CAD 0.15 per common share). The dividend is payable on November 18, 2025 to shareholders of record at the close of business on November 4, 2025. The Special Dividend is designated an eligible dividend for purposes of section 89 of the Income Tax Act (Canada).
The company reported a current cash balance of CAD 18.9 million, no debt, and profitability for the last six quarters. The Board stated it may or may not declare additional special dividends in the future. Shareholders do not need to act to receive the payment and are advised to consult financial advisors about tax treatment.
Covalon (OTCQX: CVALF) announced it will participate in the Planet MicroCap Showcase: TORONTO on October 22, 2025, with CEO Brent Ashton in a fireside chat at 12:30 p.m. ET.
The session will highlight Covalon’s positioning as a microcap medical technologies company — including claims of profitability, a debt-free and cash-rich balance sheet, recent clinical and health-economic evidence supporting its products, and plans to use cash to accelerate shareholder value. The discussion will cover product validation, growth catalysts, and the company’s view on U.S. macro volatility.
Investors can register to attend in person or watch the presentation online; additional company information is available at www.covalon.com and on social media.
Covalon (OTCQX: CVALF) will exhibit at the ANCC National Magnet & Pathway Conference in Atlanta on October 8–10, 2025, where it will showcase products and new clinical evidence aimed at reducing CLABSIs, SSIs, and MARSIs.
Covalon will present peer‑reviewed VALGuard® Line Guard data from Children’s Hospital at Montefiore showing an association with reduced CLABSIs, including a sustained zero‑CLABSI period in a pediatric ICU, and will host authors at its booth #2535. VALGuard is indicated to cover IV connections but is not FDA cleared for infection prevention or CLABSI reduction.
Covalon Technologies (OTCQX: CVALF) announced its participation in the Association of Pediatric Hematology/Oncology Nurses (APHON) 49th Annual Conference from September 25-27, 2025, in Providence, Rhode Island. The company will showcase its vascular access portfolio, highlighting recent clinical evidence and economic findings.
Key achievements include a peer-reviewed study showing 78% reduction in hospital-wide CLABSI rates using VALGuard® Line Guard at Children's Hospital at Montefiore. The company will present its product line including VALGuard® Line Guard, CovaClear® Dressings, IV Clear® Dressings, and SurgiClear®, designed to improve patient outcomes while providing cost savings for hospitals.
Covalon Technologies (OTCQX: CVALF), an advanced medical technologies company, has announced significant leadership changes. Abe Schwartz, the company's largest shareholder and board member since 2008, has been elected as the new Chair of the Board, replacing Amir Boloor, who is stepping down as Executive Chair and director.
Schwartz, who previously served as Board Chair from 2012 to 2020, brings 50 years of experience as a Healthcare and I.T. industry entrepreneur. The company is currently in a strong financial position, being profitable, debt-free, and holding $18 million in cash. Joe Cordiano will continue serving as Lead Independent Director.
Covalon Technologies (OTCQX: CVALF) announced its participation in the Association for Vascular Access (AVA) Annual Scientific Meeting in Orlando from September 18-21, 2025. The company will showcase its vascular access and infection prevention solutions at Booth #515.
A recent peer-reviewed study from the Children's Hospital at Montefiore, published in JAVA, demonstrated that Covalon's VALGuard® Line Guard helped achieve a significant reduction in Central Line-Associated Blood Stream Infections (CLABSIs), including a period of zero CLABSIs in the Pediatric Critical Care Unit.
The company will feature three key products: VALGuard® Line Guard for IV line protection, CovaClear® dressings for IV securement, and IV Clear® dressings with antimicrobial protection, showcasing their integrated approach to infection prevention and line management.
Covalon Technologies (OTCQX: CVALF) announced significant results from a peer-reviewed clinical study of its VALGuard® Vascular Access Line Guard published in the Journal of the Association for Vascular Access. The study, conducted at the Children's Hospital at Montefiore, demonstrated remarkable effectiveness in reducing central line-associated bloodstream infections (CLABSIs).
The study revealed a 100% decrease in CLABSI rates in the Pediatric Critical Care Unit (PCCU), dropping from 1.8 CLABSIs per 1,000 line days to 0.0 over 16 months post-implementation. The Acute Care Units saw a 53% reduction in CLABSI rates, decreasing from 1.5 to 0.7 CLABSIs per 1,000 line days.
Covalon Technologies (OTCQX: CVALF) reported strong fiscal Q3 2025 results with sequential quarter-over-quarter revenue growth of 10.4% to $8.4 million and Adjusted EBITDA growth of 52% to $0.9 million. The company's trailing twelve months showed revenue growth of 13% and Adjusted EBITDA increase of 116%.
Key highlights include: U.S. Vascular Access and Surgical Consumables revenue up 35% YTD, Advanced Wound Care showing 40% sequential growth, and International sales up 35% YTD. The company maintains a strong balance sheet with $18 million in cash and no debt. Upcoming clinical evidence studies for VALGuard® Line Guard and CovaClear IV® products will be presented at major scientific meetings, expected to drive product adoption.
Covalon Technologies (TSXV: COV; OTCQX: CVALF), a medical technologies company, has achieved DTC eligibility for its shares in the United States, enabling electronic clearing and settlement on the OTCQX Market. This development streamlines trading processes and reduces transaction costs for U.S. investors.
The company also confirmed the previously announced appointment of Kim Crooks to its Board of Directors and the granting of 150,000 stock options at an exercise price of $2.50 per share. The options will vest over three years and expire in five years, subject to TSX Venture Exchange requirements and shareholder approval at the 2026 Annual General Meeting.
Covalon Technologies (OTCQX:CVALF), an advanced medical technologies company, has scheduled its Q3 Fiscal 2025 financial results announcement for Wednesday, August 21, 2025, before markets open.
The company will host a conference call and webcast at 8:30am ET on the same day to discuss the results. Participants can join via webcast or dial in using various phone numbers, including North American Toll-Free: 1-800-549-8228. The event will include a Q&A session where management will address questions from participants.